This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Fennec Pharmaceuticals Inc.

Drug Names(s): ADH300004

Description: Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU). Normally, 5-FU is rapidly broken down in the body by an enzyme known as dihydropyrimidine dehydrogenase (DPD). Eniluracil irreversibly inhibits DPD, thereby substantially slowing the breakdown of 5-FU and prolonging exposure of the tumor cells to the drug.

There is another important potential benefit of the combination of eniluracil and 5-FU: the combination may expand the range of cancers that respond to 5-FU. Some tumors have inherently high levels of DPD that result in resistance to 5-FU. Eniluracil may eliminate these high levels of DPD activity in the tumor, thereby potentially expanding the use of 5-FU into new cancer indications.

Deal Structure: Sodium Thiosulfate was originally developed by Adherex. In September 2014, Adherex Technologies Inc. announced that it filed a Notice of Alteration with the British Columbia Registrar of Companies changing the name of the Company from Adherex Technologies Inc. to Fennec Pharmaceuticals Inc.

Adherex and GSK
In July 2005, Adherex in-licensed eniluracil from GlaxoSmithKline (GSK). Under the terms of the agreement, Adherex paid no upfront cash for the license, GSK made an equity investment of $3 million to assist in its further development, and GSK retained option rights to buy back eniluracil at certain specified times during development in return for milestone payments to Adherex of up to US $120 million and up to double-digit sales royalties, depending on when and if GSK exercises one of its options.

In January 2007, Adherex Technologies amended its July 14, 2005 Development and License Agreement for eniluracil with GlaxoSmithKline by purchasing all of GSKs...See full deal structure in Biomedtracker

Partners: GlaxoSmithKline plc

Eniluracil News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug